BioPharma Reporter

MAY 10, 2021

Flagship Pioneering has unveiled Laronde: a platform company developing Endless RNA.

RNA 98

RNA Engineer Medicine Protein 98

Scienmag

AUGUST 4, 2020

Led by Boyce Thompson Institute’s Andrew Nelson, four partners will identify RNA modifications and develop resources that may lead to hardier crops Credit: Photo credit: Anna Nelson Dittrich ITHACA, NY, August 4, 2020 — RNA perform a variety of functions in cells, helping with everything from regulating genes to building proteins.

RNA 74

RNA Bioinformatics Protein Gene 74

Pharmaceutical Technology

MAY 25, 2023

ElevateBio has raised $401m in a Series D financing round for advancing its technology platforms to expedite the design, production and development of cell and gene therapies. The technology platforms include the Life Edit gene editing platform, an RNA, cell, protein, vector engineering and induced pluripotent stem cells (iPSCs) platform.

Gene Therapy 243

Gene Therapy Gene Gene Editing Development 243

Pharmaceutical Technology

DECEMBER 11, 2022

The first subject was dosed in the trial, which is designed to evaluate the safety, tolerability and immunogenicity of a nucleoside-modified RNA-based combination vaccine approach. 5 Omicron sublineages spike proteins. 5 for usage in children aged five to under 12 years.

Vaccine 289

Vaccine Vaccination Gene Therapy Gene 289

Pharmaceutical Technology

APRIL 26, 2023

MiNA Therapeutics has entered into a research collaboration and option licensing agreement with BioMarin Pharmaceutical to speed up the development of therapeutic ribonucleic acid activation (RNAa) candidates to treat rare genetic diseases. BioMarin may then license the assets fully to develop and commercialise them across the globe.

Development 130

Development Genetic Disease Genetics Gene Therapy 130

Worldwide Clinical Trials

APRIL 15, 2025

Despite their clinical heterogeneity, these diseases often share overlapping pathological mechanisms, including protein misfolding and aggregation, synaptic dysfunction, neuroinflammation, and axonal degeneration. Although PET tracers for -syn are in development, they are not yet available for clinical use.

Clinical Trials 100

Clinical Trials Clinical Trials Trials Protein 100

BioTech 365

MAY 10, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Flagship debuts Laronde to develop RNA-based meds that could turn cells into protein factories.Flagship debuts Laronde to develop RNA-based meds that could turn cells into protein factories … Continue reading →

RNA 40

RNA Protein Development Research 40

Worldwide Clinical Trials

AUGUST 14, 2024

Hematological cancer cells can also develop resistance to therapies over time, reducing treatment effectiveness. Molecular Biomarkers : Encompass various molecules, such as RNA and metabolites, to reflect the physiological state of the cells and their disease pathways.

Genetics 195

Genetics Protein Gene Genotype 195

pharmaphorum

SEPTEMBER 1, 2020

The world of drug discovery and chemical probes is still protein-centric and developing highly selective small molecules targeting RNA is often considered to be an insurmountable challenge. Why You Should Attend the RNA- Targeted Drug Discovery Summit. The post 3rd RNA-Targeted Drug Discovery Summit appeared first on.

RNA 52

RNA Drugs Protein Clinical Development 52

pharmaphorum

MAY 14, 2021

Biogen has made a further push into RNA-based drug discovery via a collaboration with Envisagenics, which applies artificial intelligence RNA sequencing data to discover new drug targets and therapeutics. It’s not the first partnership for Biogen in the RNA splicing area.

RNA 60

RNA Licensing Licensing Genetics 60

XTalks

AUGUST 5, 2020

In recent webinars by Genuity Science, formerly known as WuXi NextCODE, experts from the biotech and pharma industries spoke about leveraging the power of single cell RNA sequencing platforms and solutions in conjunction with machine learning technologies such as AI in cell biology and disease research. The Power of Single Cell Technology.

Gene Expression 112

Gene Expression Development RNA Drugs 112

Pharmaceutical Technology

JUNE 23, 2022

Mpro has become the main focus of intense research and treatment development as it is vital for viral replication. It functions as a molecular scissor by slicing long chains of virus’ polypeptide proteins into smaller component proteins. These smaller segments can subsequently fold and develop to create new virus particles.

Drugs 130

Drugs Protein Genome Genomics 130

Scienmag

APRIL 27, 2022

CHAPEL HILL, NC – Inside embryonic cells, specific proteins control the rate at which genetic information is transcribed from DNA to messenger RNA – a crucial regulatory step before proteins are created. Then, organs develop and hopefully function properly.

Scientist 83

Scientist Gene RNA Protein 83

The Pharma Data

JANUARY 5, 2021

Durham, North Carolina-based Ribometrix announced a strategic collaboration deal with Genentech , a Roche company, to identify and advance novel RNA-targeted small molecule therapeutics. Targeting RNA is believed to be a way to develop therapeutics for so-called undruggable proteins.

RNA 52

RNA Protein Bioavailability DNA 52

Pharmaceutical Technology

JULY 5, 2022

Researchers at the UNC School of Medicine have discovered that hepatitis A virus (HAV) replication needs particular interactions between the human protein ZCCHC14 and TENT4 poly(A) polymerases, a group of enzymes. In addition, the scientists later found that the HAV needs TENT4A/B for its replication.

Protein 130

Protein RNA Genomics Genome 130

pharmaphorum

JANUARY 6, 2022

Roivant is the latest pharma group to take a position in the emerging field of therapies targeted at RNA splicing, licensing exclusive rights to a drug developed by a unit of Japanese drugmaker Eisai. . The post Roivant joins RNA splicing push with Eisai deal appeared first on.

RNA 52

RNA Licensing Licensing Development 52

Scienmag

FEBRUARY 7, 2022

The SARS-CoV-2 nucleoprotein is the main protein in viral particles. It folds the RNA of the virus into a compact structure. COVID-19 patients usually develop antibodies (immunity proteins that are specifically […].

Antibody 82

Antibody RNA Protein Development 82

pharmaphorum

JULY 20, 2022

Armed with a $100 million second-round financing, CAMP4 Therapeutics is preparing to start the first clinical trial of a drug targeting regulatory RNA (regRNA) molecules that can be used to fine-tune the expression of genes. ” The post CAMP4 raises $100m to take lead RNA drugs into clinic appeared first on. .

RNA 52

RNA Genetic Disease Drugs Protein 52

pharmaphorum

OCTOBER 5, 2022

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule. billion deal in 2018. The aim will be to identify promising candidates in areas of “unmet patient need.”

RNA 105

RNA Genetics Dermatology Antibody 105

pharmaphorum

AUGUST 18, 2020

Could AI prevent future pandemics by developing an armoury of drugs that work against all coronaviruses? This is a question that a consortium of European pharma companies hopes to answer as it aims to rapidly develop new therapies to combat the pandemic. But also included in the 77.7

Protein 121

Protein Pharma Companies RNA Drugs 121

Pharmaceutical Commerce

AUGUST 28, 2024

The joint venture aims to disrupt pathological lncRNA interactions with RNA-binding proteins using NextRNA’s platform.

RNA 52

RNA Protein Development 52

STAT News

JULY 19, 2022

The vaccine is a recombinant protein product, developed with the same kind of approach that is used for a brand of flu vaccine. Some people who have refused Covid vaccines have expressed hesitancy over the messenger RNA vaccines produced by Moderna and the Pfizer and BioNTech partnership. Read the rest…

Vaccine 98

Vaccine Vaccination RNA Branding 98

Pharmaceutical Technology

FEBRUARY 15, 2023

The structural proteins include the capsid, pre-membrane/membrane proteins and envelope (E) proteins. The non-structural proteins NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 are involved in viral RNA replication and dampening of the host innate immune response.

Vaccine 130

Vaccine Vaccination Protein Immune Response 130

Roots Analysis

OCTOBER 30, 2023

In the past few years, Next Generation RNA therapeutics have emerged as one of the key therapeutic modalities in the modern healthcare industry. These RNA based therapeutics play a crucial role in protein production and regulation of gene functions.

RNA 40

RNA Vaccine Vaccination Development 40

XTalks

AUGUST 10, 2021

The test was developed by researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University, the Massachusetts Institute of Technology (MIT) and several Boston area hospitals. A porous membrane was engineered to capture RNA on its surface. Image source: Wyss Institute at Harvard University.

RNA 105

RNA Containment DNA Engineer 105

pharmaphorum

MARCH 11, 2022

After a period where vaccine development had fallen away, suddenly it is back in the limelight. However, for those individuals working on vaccine development, the pandemic has proven to be a validation of the important work being carried out in the field. There are very few things to be grateful for about the arrival of the pandemic.

Vaccine 81

Vaccine Vaccination Development Manufacturing 81

Scienmag

JULY 1, 2021

Almost twenty years ago, the process of RNA silencing was discovered in plants, whereby small fragments of RNA inactivate a portion of a gene during protein synthesis.

RNA 60

RNA Protein Research Gene 60

Delveinsight

AUGUST 26, 2021

Seattle biotech firm Shape Therapeutics has signed a deal potentially exceeding USD 3 billion with pharma giant Roche to bolster the development of gene therapies for Alzheimer’s and Parkinson’s disease. Shape’s RNA editing technologies can modify the RNA sequence, which makes the body’s protein building blocks.

Vaccine 98

Vaccine Vaccination Gene Therapy RNA 98

The Pharma Data

MARCH 23, 2022

Polymerase is a viral protein that directs how Ebola virus replicates its genome as it infects new hosts. The researchers discovered that Ebola virus polymerase hijacks a cellular protein called GSPT1. To treat Ebola virus infections, researchers are taking a close look at a key piece of the virus: polymerase.

Protein 52

Protein Genomics Genome Research 52

pharmaphorum

JANUARY 7, 2022

NI006 is an antibody that binds to the misfolded forms of the transthyretin protein that form the fibrils, and cause them to be cleared away by immune cells like macrophages. Tafamidis is thought to work by stabilising the misfolded proteins.

Antibody 116

Antibody Licensing Licensing Protein 116

pharmaphorum

APRIL 19, 2022

The funding will be used to continue the clinical development of lead oligonucleotide PGN-EDO51 for DMD, as well as two other oligo drugs PGN-EDODM1 for myotonic dystrophy type 1 (DM1) and PGN-EDO53, another DMD candidate. Once there, they disrupt the expression of RNA coding for disease-associated proteins.

Protein 105

Protein RNA Clinical Development Production 105

pharmaphorum

OCTOBER 31, 2022

Verge Genomics has joined a select group of biotechs who have taken a drug discovered and developed using artificial intelligence into human testing.

Genome 136

Genome Genomics Drugs RNA 136

pharmaphorum

SEPTEMBER 16, 2020

Both of these vaccines are based on RNA and in phase 3 and phase 1 testing, respectively. The amount due to be awarded by Dessau-based IDT Biologika – whose non-replicating viral vector shot is further back in development – is still being discussed, according to German broadcaster Deutsche Welle.

Vaccine 86

Vaccine Vaccination RNA Trials 86

pharmaphorum

MAY 6, 2021

Thalassaemia is a severe genetic disease that is characterised by significantly reduced production of functional beta-globin, a component of haemoglobin, the oxygen-carrying protein in the blood. It has a candidate in development that targets TMPRSS6, an enzyme that reduces levels of a protein (hepcidin) that controls iron levels in the body.

Genetic Disease 104

Genetic Disease Protein RNA Doctor 104

BioTech 365

MARCH 22, 2021

NanoString, Illumina Accelerator and Doloromics Announce GeoMx Digital Spatial Profiling Collaboration to Develop Novel Pain Therapeutics NanoString, Illumina Accelerator and Doloromics Announce GeoMx Digital Spatial Profiling Collaboration to Develop Novel Pain Therapeutics Multiplex Spatial Analysis Provides High-Content RNA and Protein … Continue (..)

Development 40

Development RNA Protein 40

The Pharma Data

JUNE 14, 2023

Scientists discover small RNA that regulates bacterial infection People with weakened immune systems are at constant risk of infection. Their research findings, published in Nature, can inform the development of future treatments for life-threatening acute infections. They named the small RNA SicX (sRNA inducer of chronic infection X).

RNA 40

RNA Regulation Scientist Bacteria 40

pharmaphorum

JANUARY 12, 2021

US biotech Atalanta Therapeutics has come out of stealth mode backed with $110m from Biogen and Roche, who have also signed separate partnerships to develop new therapies for neurological diseases using RNA interference (RNAi) technology. This could also result in development and milestone payments and royalties.

RNA 95

RNA Production Development Pharma Companies 95